| Norristown State Hospital | |
| 1001 Sterigere Street, Norristown, Pennsylvania 19401 | |
| (610) 313-1000 | |
| Not Available |
| Name | Norristown State Hospital |
|---|---|
| Type | Psychiatric Hospital |
| Location | 1001 Sterigere Street, Norristown, Pennsylvania |
| Ownership | Government - State |
| Emergency Services | No |
| Medicare ID (CCN) | 394001 |
| NPI Number | 1447233317 |
| Organization Name | PENNSYLVANIA DEPARTMENT OF HUMAN SERVICES |
| Doing Business As | NORRISTOWN STATE HOSPITAL |
| Address | 1001 Sterigere St, Norristown, PA 19401 |
| Hospital Type | Psychiatric Hospital |
| Phone Number | 610-313-1015 |
News Archive
Resverlogix Corp. announced today the completion of patient enrollment in the Phase 2 clinical study of its lead drug RVX-208. "The completion of enrollment for our Phase 2 ASSERT trial, a full 5 months ahead of our original schedule, is a very exciting achievement for our staff and our collaborators at the Cleveland Clinic.
Keryx Biopharmaceuticals, Inc. today announced that two posters on KRX-0401 were presented at the 102nd annual meeting of the American Association for Cancer Research currently ongoing at the Orange County Convention Center in Orlando, Florida. Perifosine, the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, is currently in Phase 3 clinical trials for refractory advanced colorectal cancer and multiple myeloma.
Rhesus monkeys were completely protected from the deadly Ebola virus when treated three days after infection with a compound that blocks the virus's ability to replicate. These encouraging preclinical results suggest the compound, known as GS-5734, should be further developed as a potential treatment, according to research findings to be presented tomorrow at the IDWeek conference.
Results of a landmark study led by a doctor at John Wayne Cancer Institute at Saint John's Health Center raises serious questions about the long-term survival benefits of removing a woman's ovaries during routine hysterectomy.
St. Jude Medical, Inc., a global medical device company, today announced subset data results for the Angio-Seal™ Evolution™ Vascular Closure Device Registry. The results reaffirm the excellent sealing performance of the Angio-Seal Evolution vascular closure device in patients undergoing routine diagnostic and interventional cardiac catheterization procedures.
› Verified 2 days ago
News Archive
Resverlogix Corp. announced today the completion of patient enrollment in the Phase 2 clinical study of its lead drug RVX-208. "The completion of enrollment for our Phase 2 ASSERT trial, a full 5 months ahead of our original schedule, is a very exciting achievement for our staff and our collaborators at the Cleveland Clinic.
Keryx Biopharmaceuticals, Inc. today announced that two posters on KRX-0401 were presented at the 102nd annual meeting of the American Association for Cancer Research currently ongoing at the Orange County Convention Center in Orlando, Florida. Perifosine, the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, is currently in Phase 3 clinical trials for refractory advanced colorectal cancer and multiple myeloma.
Rhesus monkeys were completely protected from the deadly Ebola virus when treated three days after infection with a compound that blocks the virus's ability to replicate. These encouraging preclinical results suggest the compound, known as GS-5734, should be further developed as a potential treatment, according to research findings to be presented tomorrow at the IDWeek conference.
Results of a landmark study led by a doctor at John Wayne Cancer Institute at Saint John's Health Center raises serious questions about the long-term survival benefits of removing a woman's ovaries during routine hysterectomy.
St. Jude Medical, Inc., a global medical device company, today announced subset data results for the Angio-Seal™ Evolution™ Vascular Closure Device Registry. The results reaffirm the excellent sealing performance of the Angio-Seal Evolution vascular closure device in patients undergoing routine diagnostic and interventional cardiac catheterization procedures.
› Verified 2 days ago
Suburban Community Hospital Acute Care Hospital Location: 2701 Dekalb Pike, Norristown, Pennsylvania 19401 Phone: (215) 278-2000 | |
Valley Forge Medical Center And Hospital Acute Care Hospital Location: 1033 W Germantown Pike, Norristown, Pennsylvania 19401 Phone: (215) 539-8500 | |
Norristown State Hospital Psychiatric Hospital Location: 1001 Sterigere Street, Norristown, Pennsylvania 19401 Phone: (610) 313-1000 | |
Montgomery County Emergency Service, Inc Psychiatric Hospital Location: 50 Beech Drive, Norristown, Pennsylvania 19403 Phone: (610) 279-6100 |